Recent Updates
Recently added Catalysts

EXS74539

Phase 1

Solid Tumor | Small molecule | Oncology |Recursion Pharmaceuticals, Inc.|Last Updated: Apr 8, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment40
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsPHASE1 RECRUITING 40 — — Apr 1, 2026Mar 1, 2029Apr 8, 20262 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Up to 3 years
Number of Participants with Dose-limiting Toxicity (DLT)
Up to 28 days
Number of Participants with Dose Interruptions and Dose Modifications
Up to 3 years
Secondary Endpoints
Maximum Concentration (Cmax) of EXS74539
Cycle 1 Day 25 and at end of treatment (up to approximately 3 years)
Time to Cmax (tmax) of EXS74539
Cycle 1 Day 25 and at end of treatment (up to approximately 3 years)
Area Under the Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-last]) of EXS74539
Cycle 1 Day 1 through end of treatment (up to approximately 3 years)
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
EXS74539EXPERIMENTALEXS74539
Interventions
NameTypeDescription
EXS74539DRUGOral administration
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites2

Key Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Histologically confirmed diagnosis of the following solid tumors: * SCLC * High grade neuroendocrine or small cell carcinomas of non-lung origin * Non-small cell lung cancer \[NSCLC\] * Prostat...

Countries:United States
Unlock Eligibility Criteria
Competitive Landscape -Other Solid Tumors 9 trials
CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK2PHASE2pembrolizumab, V503, GARDASIL
Incyte CorporationINCY1PHASE2Chemotherapy, Retifanlimab
Novartis AG Sponsored ADRNVS1PHASE1KFA115, pembrolizumab
Iovance Biotherapeutics IncIOVA2PHASE2E7 TCR-T cells, Aldesleukin
AstraZeneca PLCAZN1 — Trastuzumab deruxtecan
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT07517198primaryCompletionDate: changed
LOWMay 24, 2026NCT07517198studyFirstPostDate: changed
LOWMay 21, 2026NCT07517198NEW_TRIAL: changed
LOWMay 21, 2026NCT07517198NEW_TRIAL: changed